Bevacizumab
Chapter 5. Marketed drug analysis & forecasts Marketed drugs 67 Roche Chugais Xeloda capecitabine ; 68 Leading agent in the third-line market 68 Growth from the adjuvant market 69 Avastin as a suitable partner? 70 Pfizer Yakult Daiichis Camptosar Campto Topotecin irinotecan ; 73 Irinotecans stigma of toxicity 73 Camptosar losing grounds to competitors 74 EU physicians use irinotecan due to Avastins labeling 77 Irinotecan limited to second-line use 77 Patent expiry 77 Sanofi-Aventiss Eloxatin oxaliplatin ; 78 Gold standard for colorectal cancer 79 Neuropathy remains the main barrier 80 Generic oxaliplatin entering the EU markets 81 US patent remains protected until 2013 82 Elplat surpassing Campto in Japan 82 Genentech Roche Chugais Avastin bevacizumab ; 82 Avastin is the gold standard in the US 83 Limitations in Europe 83 Market expansion potential 84 Is toxicity a major limiting factor? 87 Cost implications of Avastin plus Erbitux 88 Bristol-Myers Squibb Merck KGaA ImClones Erbitux cetuximab ; 89 Standard therapy in third line 89 Futility of EGFR tests 90 Line extensions in colorectal cancer 91 Cost hampering the uptake 93 Competition from Vectibix 93 Forecasting assumptions and events 95 Sales forecasts to 2015 97.
Get in HCC. In the recent Annual Meeting of the American Society of Clinical Oncology, results of a phase III, randomized, placebo-controlled trial were presented in which sorafenib, an orally active multikinase inhibitor with effects on tumor-cell proliferation and tumor angiogenesis, demonstrated superior survival in advanced HCC [12]. Clinical studies are ongoing in advanced HCC with several other antiangiogenic agents. VEGF is a key mediator of angiogenesis [13]. Preclinical studies have shown that inhibition of VEGF produces a number of effects on the tumor vasculature, including vessel regression [14], vessel normalization [15, 16], and inhibition of neovascularization [17, 18]. Bevacizumab, a humanized monoclonal antibody to VEGF, improves outcomes when used in combination with standard chemotherapy in colorectal cancer and several other solid tumor types [19, 20]. In addition to its direct antiangiogenic effects, bevacizumab may improve the delivery of chemotherapy by altering tumor vasculature and decreasing the elevated interstitial pressure within tumors [15, 21]. In an attempt to develop an active systemic regimen, we performed a phase II study combining bevacizumab with gemcitabine and oxaliplatin GEMOX ; in patients with unresectable or metastatic HCC [22]. This regimen showed moderate antitumor activity with a response rate of 20% and a median progression-free survival time of 5.3 months. The identification of surrogate biologic markers to measure the effect of antiangiogenic therapy in HCC remains very challenging. Conventional tissue biopsy coupled with an analysis of MVD is hampered by the heterogeneity of tumors as well as the risks associated with obtaining serial tissue specimens in patients with a prevalence of underlying cirrhosis and coagulopathy. In this study, we explored the use of a noninvasive technique, computed tomography perfusion CTp ; scan, as a potential method to monitor changes in angiogenic parameters after bevacizumab treatment. Here, we report baseline and post-bevacizumab treatment values for CTp parameters and the correlation between these parameters and clinical efficacy in patients with advanced HCC.
Clinical Justification: 1. Avastin bevacizumab ; is a recombinant humanized monoclonal IgG1 antibody that is similar to Lucentis. 2. Protocol for use of intravitreal bevacizumab has been developed and tried in different Institutes. 3. American Academy of Ophthalmology supported the reimbursement for treating age-related macular degeneration AMD ; with intravitreal injections of bevacizumab, to meet the medical needs of many patients who have not responded to therapy with ocular photodynamic therapy OPT ; with verteporfin or intravitreal pegaptanib. 4. More than 6, 800 injections in 5, 055 patients from 68 centers in 12 countries have been documented with a low rate of ocular or systemic adverse events. 5. The use of Avastin via intravitreal injection is entirely off-label, but the clinical experiences appear that Avastin is working just as well as Lucentis. 6. Avastin is formulated for intravenous infusion, not intravitreal injection. Although Avastin is similar to Lucentis, they are different in several aspects: a. Avastin is about 3 times as large as Lucentis 149kD vs. 48kD ; - smaller molecular means better penetration to the layers of the retina; b. Avastin has a longer half-life 20 days compared to 4 hours ; - less systemic side-effects if it is significant; c. Lucentis doesn't have Fc portion in this antibody fragment, which may cause less inflammation within the eye.
Markets were burned down and destroyedat Accra, Kumasi, Koforidua, and other cities when traders refused to sell at governmentdictated prices. In February 1982, the Tamale Central Market was set ablaze, causing the destruction of large quantities of foodstuffs, drugs, and imported spare parts. Then John Ndeburge, the Northern Regional Secretary, set up a five-member committee of inquiry to.
Pharmacist articles h ts 070 cfm sloan-kettering - find a clinical trial open in a new window ; bevacizumab appears to make a number of drugs work better in colorectal cance irinotecan, cetuximab, and bevacizumab are drugs approved for treating advanced colorectal cancer.
Synopsis Researchers presenting at the annual meeting of the American Society of Clinical Oncology said that patients with non-small cell lung cancer who took bevacizumab Avastin ; in combination with chemotherapy took longer to relapse than patients who were treated with chemotherapy alone. Data from this phase III trial showed that the average length of time before recurrence in patients on the combination regimen was 6.4 months compared with 4.5 months in those taking chemotherapy alone. According to the report, 51.9% of patients were alive after 1 year of treatment, compared with 43.7% on chemotherapy alone. At 2 years, 22.1% of patients on the combination were alive compared with 16.9% on chemotherapy alone. The trial did not include patients with brain metastases. According to the report, the most serious side effect was life-threatening or fatal bleeding, mainly from the lungs. This occurred in 1.7% of patients in the Avastin group and did not occur at all in the chemotherapy alone group. Non-life threatening bleeding occurred in 5% of patients in the Avastin group compared to 1% in the chemotherapy alone group and bexarotene.
50. Midy V, Plouet J. Vasculotropin vascular endothelial growth factor induced differentiation in cultured osteoblasts. Biochem Biophys Res Commun 1994; 199: 3806. Zelzer E, Mamluk R, Ferrara N, Johnson RS, Schipani E, Olsen BR. VEGFA is necessary for chondrocyte survival during bone development. Development 2004; 131: 216171. Gerber H-P, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nature Med 1999; 5: 6238. Haigh JJ, Gerber H-P, Ferrara N, Wagner EF. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development 2000; 127: 144553. Modlich U, Kaup FJ, Augustin HG. Cyclic angiogenesis and blood vessel regression in the ovary: blood vessel regression during luteolysis involves endothelial cell detachment and vessel occlusion. Lab Invest 1996; 74: 77180. Ferrara N, Chen H, Davis-Smyth T, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998; 4: 33640. Zimmermann RC, Xiao E, Bohlen P, Ferin M. Administration of antivascular endothelial growth factor receptor-2 antibody in the early follicular phase delays follicular selection and development in the rhesus monkey. Endocrinology 2002; 143: 2496502. Ryan AM, Eppler DB, Hagler KE, et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999; 27: 7886. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor VEGF ; signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. J Pathol 2004; 165: 3552. Kiessling F, Farhan N, Lichy MP, et al. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia 2004; 6: 21323. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996; 93: 1476570. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 233542. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 1457. Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity on VEGF-C. EMBO J 1997; 16: 3898911. Jia H, Bagherzadeh A, Bicknell R, Duchen MR, Liu D, Zachary I. Vascular endothelial growth factor VEGF ; -D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J Biol Chem 2004; 279: 3614857. Koolwijk P, Peters E, van der Vecht B, et al. Involvement of VEGFR-2 kdr flk-1 ; but not VEGFR-1 flt-1 ; in VEGF-A and VEGF-C induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro . Angiogenesis 2001; 4: 5360. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002; 94: 148493. Medinger M, Mross K, Zirrgiebel U, et al. Phase I dose escalation study of the highly potent VEGF receptor tyrosine kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastases. Proc Soc Clin Oncol 2004; 23: 208.
Caregivers who support their spouse or partner in living with bone marrow diseases discuss common needs and concerns with people who truly understand this difficult situation, including ways to maintain positive communication and healthy relationships while caring for yourself, your partner, and your family and bidil.
1. Ferrara N, Hillan KJ, Novotny W. Bevacizumab Avastin ; , a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328 Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967 McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003; 9: 713 Stewart VR, Sidhu PS. New directions in ultrasound: microbubble contrast. Br J Radiol 2006; 79: 188 Bloch SH, Dayton PA, Ferrara KW. Targeted imaging using ultrasound contrast agents. Progress and opportunities for clinical and research applications. IEEE Eng Med Biol Mag 2004; 23: 18 LindnerJR. Microbubbles in medical imaging: current applications and future directions. Nat Rev Drug Discov 2004; 3: 527 Klibanov AL. Targeted delivery of gas-filled microspheres, contrast agents for ultrasound imaging. Adv Drug Deliv Rev 1999; 37: 139 Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004; 101: 3 Solorzano CC, Baker CH, Bruns CJ, et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787 ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 2001 ; 16: 359 70. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401 Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011 Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581 Luo J, Guo P, Matsuda K, et al. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer 2001 ; 92: 361 9. Itakura J, IshiwataT, Shen B, Kornmann M, Korc M. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000; 85: 27 Niedergethmann M, Hildenbrand R, Wostbrock B, et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002; 25: 122 Bruns CJ, Shrader M, Harbison MT, et al. Effect of the vascular endothelial growth factor receptor-2 antibody DC101plus gemcitabine on growth, metastasis, and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 2002; 102: 101 Bockhorn M, Tsuzuki Y, Xu L, Frilling A, Broelsch CE, Fukumura D. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res 2003; 9: 4221 McBride G. Researchers optimistic about targeted drugs for pancreatic cancer. J Natl Cancer Inst 2004; 96: 1570 Kindler HL, Friberg G, Stadler WM, et al. Bevacizumab B ; plus gemcitabine G ; in patient pts ; with advanced pancreatic cancer PC ; : updated results of a multi-center phase II trial. J Clin Oncol Meet Abstr ; 2004; 22: 4009. Korpanty G, Grayburn PA, Shohet RV, Brekken RA. Targeting vascular endothelium with avidin microbubbles. Ultrasound Med Biol 2005; 31: 1279 Beck AW, LusterTA, Miller AF, et al. Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer 2006; 118: 2639 Ge AZ, Butcher EC. Cloning and expression of a cDNA encoding mouse endoglin, an endothelial cell TGF-h ligand. Gene 1994; 138: 201 Ran S, Huang X, Downes A, Thorpe PE. Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. Neoplasia 2003; 5: 297 Brekken RA, Huang X, King SW, Thorpe PE. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998; 58: 1952 Brekken RA, OverholserJP, StastnyVA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor VEGF ; receptor 2 KDR Flk-1 ; activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000; 60: 5117 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophageT4. Nature 1970; 227: 680 Rouan SK, Otterness IG, Cunningham AC, Holden HE, Rhodes CT. Reversal of colchicine-induced mitotic arrest in Chinese hamster cells with a colchicinespecific monoclonal antibody. J Pathol 1990; 137: 779 Weller GE, Wong MK, Modzelewski RA, et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res 2005; 65: 533!
The search also found no evidence on outcomes of bevacizumab in patients who progressed after interferon alfa, sorafenib, or sunitinib and bilberry.
Ogy Group ECOG ; 3200 study, the use of bevacizumab with an oxaliplatin-containing regimen was explored in the second-line setting. The study population included 822 patients who had undergone a 5-FUbased therapy, mostly bolus, and irinotecan, either separately or together, but who had not received bevacizumab. Second-line therapy was bevacizumab alone, FOLFOX alone, or FOLFOX plus bevacizumab. The FOLFOX plus bevacizumab group had a small but statistically significant improvement in median OS compared with the FOLFOX-alone group 12.5 vs 10.7 months; P 0.002; Table 2 ; . The bevacizumab-alone arm in this trial was terminated prematurely due to concerns of inferior efficacy.10 The Three Regimens of Eloxatin Evaluation TREE ; -2 trial is assessing bevacizumab in first-line combination chemotherapy with oxaliplatin. It is a small extension of TREE-1, which compared oxaliplatin and bolus, infusional, or oral fluoropyrimidine regimens in first-line use and reported a similar median OS in all treatment groups. Interim TREE-2 results show that adding bevacizumab increased the RR in all groups, but OS data have not yet been reported. A cross-study comparison showed that overall RR improved from 39% among those who received modified FOLFOX in TREE-1 to 49% in those who received this regimen plus bevacizumab in TREE-2.11 Bevacizumab in laterline therapies Bevacizumab shows greater efficacy when used as earlier-line therapy rather than in later-line settings.
Bevacizumab medicine
By most renal cancers, 19 suggesting that combina- ter understanding of the biology of each individual tions of bevacizumab and inhibitors of members of type of cancer. the fibroblast growth factor family may have promWe are indebted to the Surgery Branch research nurses and imise for treatment of this disease. It is likely that the munotherapy fellows, the day hospital nursing staff, Don White, Maria Merino, W. Marston Linehan, Richard Klausner, Gwen Fyfe, future of antiangiogenic therapy will require a ra- and William Novotny for their invaluable assistance in the conduct tional combination of inhibitors, directed by a bet- of this study and bioflavonoids.
Been developing under the Ministry of Production's Foreign Trade Office. The ProCrdoba agency is responsible for everything inherent to the promotion of Crdoba's foreign trade and places special emphasis on helping SMEs to achieve an international profile. Another of its goals is managing the implementation of active policies enhancing the positioning of Crdoba's businesses and products, in particular, small and medium-sized enterprises. Formal contacts between the Agency and the different foreign trade players of the Province are through an Advisory Council. This Advisory Council includes one representative from each business organization either directly involved in foreign trade or important in some way for the Province's exports. In this case, it is clear that the Economic Development Agencies were created in different towns of the province to ensure that the different regions of the province are present and represented. In budgetary terms, ProCrdoba uses 30% of the million pesos available on an annual basis for operating and staff expenses and spends the remaining 70% on trade promotion activities. Nevertheless, there is insufficient coordination between the activities carried out at provincial level with those carried out by the Exportar Foundation at national level. The creation of the Exportar Foundation during the last decade, as a public-private institution, prompted the provision of assistance so that exporting companies could expand and diversify their presence abroad. The Foundation coordinates its activities with those of the Ministry of Foreign Affairs, International Trade and Public Worship through its Embassies, Consulates and the Economic Trade Sections of the different Argentinian offices worldwide. One of its main activities is organizing international fairs and trade missions, which had a combined budget of 10 million pesos in 2002. It also arranges business agendas and provides advice and training. All this makes it possible, at least in principal, to leverage the international presence of Argentinian products. Summing up, there are multiple agencies carrying out the same kind of activities fairs, trade missions, training of businessmen, but these are "sadly very poorly coordinated among themselves" IERAL [2001] ; . The experience of all these initiatives is that the different regions or areas of an economic community need to be integrated to achieve their goals. The challenge for our country is to articulate all the local or regional efforts, because this would guarantee to national government that local or regional trade policies were properly designed and that no regions were excluded. This experience repeats that of other federal countries of Latin America according to Jorge Schiavon's [2004] analysis of the rise of national and subnational organizations in Mexico.
Ii244 autocrine growth factors for mesothelioma, and different strategies aimed at blocking the autocrine loops have been recently explored [28, 29]. Three VEGF inhibitors, SU5416, bevacizumab and thalidomide, are currently evaluated in phase II studies in mesothelioma patients. Imatinib mesilate and PTK787, two PDGF-associated tyrosine kinase inhibitors, are also under clinical investigation. In addition, $ 70% of malignant mesotheliomas have high level of expression of EGFR, and a subset of cell lines derived from MPM patients express both EGFR and transforming growth factor-a, suggesting an autocrine role even for EGFR. However, two pivotal studies testing EGFR-tyrosine kinase inhibitors have shown only limited level of activity [30, 31]. Chemical or thoracoscopic either medical or videoassisted ; pleurodesis is useful in preventing fluid re-accumulation and should be performed as early as possible. Intrapleural administration of drugs or photodynamic therapy allows direct delivery to the pleural surfaces, but therapy administered in this manner usually fails to adequately penetrate the tumor and underlying tissues. With disease progression, trapped lung can occur with tumor involvement of the visceral pleura. Once trapped lung syndrome develops, pleurodesis is unlikely to be successful. Small catheter drainage may provide an alternative to inpatient pleurodesis, especially for patients with advanced disease, but carries the risk of tumor metastasis along the catheter tract. Pleuroperitoneal shunting is not recommended because of the potential risk of enhancing malignant spread to the peritoneal cavity. If dyspnea does not improve after adequate management of the pleural effusion, supplementary oxygen and opioids may help to reduce breathlessness and biperiden.
| Bevacizumab without prescriptionSymptoms are what you feel when your asthma is not under control.
Advanced colorectal cancer: in combination with 5 fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease, and as a single agent in patients who have failed an established 5 fluorouracil containing treatment regimen. Oxaliplatin Eloxatin, Sanofi Synthelabo ; is a water soluble platinum-based cytotoxic compound that cross links DNA, preventing replication and hence cell division. At the time of the original appraisal, oxaliplatin was only licensed for the first-line treatment of adults with advanced colorectal cancer in combination with 5-fluorouracil. In December 2003, the marketing authorisation was extended to "the treatment of metastatic colorectal cancer in combination with 5-fluorouracil and folinic acid". Raltitrexed Tomudex, AstraZeneca UK Ltd ; inhibits the enzyme thymidylate synthetase, which is involved in DNA synthesis. Raltitrexed has market authorisation in the UK for the palliative treatment of advanced colorectal cancer where 5-Fluorouracil and folinic acid based regimens are either not tolerated or inappropriate. Cetuximab Erbitux, Merck KGaA ; is a recombinant monoclonal antibody that blocks the human epidermal growth factor receptor EGFR ; and thus inhibits the proliferation of cells dependent on EGFR activation for growth. UK marketing authorisation for the use of cetuximab in advanced colorectal cancer is anticipated for mid 2004. ; Bevacizumab in the US: Avastin, Genentech Inc ; is a recombinant humanized monoclonal IgG1 antibody that acts as an angiogenesis inhibitor by targeting the biologic activity of human vascular endothelial growth factor VEGF ; , which stimulates new blood vessel formation in the tumour. UK marketing authorisation for the use of bevacizumab is anticipated in early 2005. ; Intervention s ; Irinotecan, oxaliplatin, raltitrexed, cetuximab, and bevacizumab ; People with advanced colorectal cancer 5-fluorouracil and folinic acid and bisacodyl.
What is Diabetic Retinopathy? Diabetic Retinopathy occurs when diabetes damages the tiny blood vessels inside the retina, the light-sensitive tissue at the back of the eye. A healthy retina is necessary for good vision. Diabetic Retinopathy usually affects both eyes. What is Diabetic Macular Edema? Diabetic Macular Edema, a subset of diabetic retinopathy, is a leading cause of vision loss for Americans under the age of 65. Retinal blood vessels in diabetic's eyes deteriorate and leak, causing the retina to swell. A minority of cases receive long-term benefit from laser treatment. What is Uveitis? An autoimmune condition, uveitis manifests itself as an inflammation inside the eye, that can lead to sudden or gradual vision loss and bevacizumab.
|
Purpose: This phase II trial investigated the safety and efficacy of two doses of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, plus fluorouracil FU ; leucovorin LV ; versus FU LV alone in patients with metastatic colorectal cancer. Patients and Methods: One hundred four previously untreated patients with measurable metastatic colorectal cancer were randomly assigned to one of the following three treatment groups: 36 to FU 500 mg m2 ; LV 500 mg m2 ; alone, 35 to FU LV low-dose bevacizumab 5 mg kg every 2 weeks ; , and 33 to FU high-dose bevacizumab 10 mg kg every 2 weeks ; . FU LV was given weekly for the first 6 weeks of each 8-week cycle. Results: Compared with the FU LV control arm, treatment with bevacizumab at both dose levels ; plus FU LV resulted in higher response rates control arm, 17%, 95% confidence interval [CI], 7% to 34%; low-dose arm, 40%, 95% CI, 24% to 58%; high-dose arm, 24%, 95% CI, 12% to 43% ; , longer median time to disease progression control arm, 5.2 months, 95% CI, 3.5 to 5.6 months; low-dose arm, 9.0 months, 95% CI, 5.8 to 10.9 months; high-dose arm, 7.2 months, 95% CI, 3.8 to 9.2 months ; , and longer median survival control arm, 13.8 months; 95% CI, 9.1 to 23.0 months; low-dose arm, 21.5 months, 95% CI, 17.3 to undetermined; high-dose arm, 16.1 months; 95% CI, 11.0 to 20.7 months ; . After cross-over, two of 22 patients had a partial response to bevacizumab alone. Thrombosis was the most significant adverse event and was fatal in one patient. Hypertension, proteinuria, and epistaxis were other potential safety concerns. Conclusion: The encouraging results of this randomized trial support further study of bevacizumab 5 mg kg plus chemotherapy as first-line therapy for metastatic colorectal cancer. J Clin Oncol 21: 60-65. 2003 by American Society of Clinical Oncology and bleomycin.
Treated with ZD6474, 100 mg day or 300 mg day, plus docetaxel, 75 mg m2, every 21 days for the phase I, open-label portion of the study. The most common adverse event observed was rash 67% of patients experienced grade 3 rash ; . Seven patients experienced grade 3 4 myelosuppression. Preliminary pharmacokinetic analyses did not show any effects on docetaxel exposure of ZD6474 treatment. The double-blind, randomized phase of this study is ongoing. ZD6474 is also currently being tested alone or in combination with paclitaxel carboplatin as first-line therapy for NSCLC. CONCLUSION The success of bevacizumab in a randomized phase III setting for the treatment of colorectal cancer has raised hopes that antiangiogenic therapies will provide similar benefits for the treatment of other tumor types. However, these results follow the release of data from the pivotal phase III study in patients with breast cancer, which were disappointing. Why were these results so different? Both tumor types express high levels of VEGF; however, as has been reported for EGFR in lung cancer, high expression may not necessarily correlate with response to targeted agents. Yet, recent results in NSCLC have demonstrated genetic mutations in the EGFR that correlate with response to specific EGFR-targeted agents. It is possible that, with time, similar predictive markers may be identified for VEGF-based therapies as well. Currently, a wide array of antiangiogenic compounds are in development. The results of ongoing studies are needed to determine if improved response rates and survival can be achieved for specific tumor types by inhibiting different angiogenic factors. Although the concept of inhibiting angiogenesis as a treatment modality for cancer was first suggested over three decades ago, finding a place for these therapies in clinical practice has been a slow and challenging process. With the positive results of bevacizumab in colorectal cancer, enthusiasm for antiangiogenic agents has been renewed, and it appears that the time has finally come to include these agents among the therapeutic options for the treatment of cancer.
The pharmacokinetics of bevacizumab did not appear to be affected by dosing of concomitant chemotherapies, including doxorubicin, carboplatin paclitaxel, 5-FU FA, capecitabine, and IFL. With the exception of irinotecan, the pharmacokinetics of these chemotherapeutic drugs were not affected by bevacizumab. In Study AVF2107g, irinotecan concentrations were not affected when dosed in combination with bevacizumab; however, there was an estimated 33% increase in exposure to SN38, the active metabolite of irinotecan, which could be a cause of the increased incidence of diarrhoea. Discontinuation due to adverse events and boniva.
|
